Evidence map›Paper›PMID 41152367›Full record

ArticleScientific reports2025

ADME related patterns to predict the prognosis and immune therapy of colon cancer patients.

Yinbei Liu, Jie Liu, Xing Tu, Juan Nie, Hong Li, Guanzheng Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yinbei Liu *Medical School, Hubei Minzu University, Enshi, 445000, Hubei, China. 956833554@qq.com.
Jie Liu *Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, Hubei, China.
Xing TuChinese Medicinal Materials Products Quality Supervision and Inspection Center in Wuling Mountainous Area, Hubei Minzu University, Enshi, 445000, China.
Juan NieMedical School, Hubei Minzu University, Enshi, 445000, Hubei, China.
Hong LiMedical School, Hubei Minzu University, Enshi, 445000, Hubei, China.
Guanzheng YuMedical School, Hubei Minzu University, Enshi, 445000, Hubei, China.

Funding

Development of a Pulsatilla Saponin B4-Targeted Nanodelivery System and Evaluation of Its In Vitro Anti-Liver Cancer Activity ZZD24018Exploring the Mechanism of Liuwei Shenhua Granules in Treating Rheumatoid Arthritis Based on m6A Methylation PT022306
6 · The paper itself

Abstract

Genes involved in absorption, distribution, metabolism, and excretion (ADME) regulate drug pharmacokinetics, yet their prognostic value in colorectal cancer (CRC) remains underexplored. This study develops an ADME-related prognostic index for colorectal adenocarcinoma (COAD). Gene expression and clinical data from 430 COAD patients in The Cancer Genome Atlas (TCGA) were analyzed to identify differentially expressed ADME genes. Functional enrichment analysis, immune cell infiltration profiling, immunotherapy response prediction, and mutation burden comparison were performed between high-risk (HR) and low-risk (LR) groups. ADME genes demonstrated distinct functional patterns between risk groups. The LR group exhibited enrichment in drug metabolism pathways, whereas the HR group was predominantly associated with extracellular matrix-receptor interactions and focal adhesion signaling. The ADME-related prognostic index correlates with immune cell infiltration and may serve as a therapeutic biomarker for CRC patients.

Indexed as

AdenocarcinomaColonic NeoplasmsColorectal NeoplasmsImmunotherapyBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorADME genesColon cancerImmune microenvironmentPrognostic indexTherapeutic biomarker

Identifiers

PMID41152367
PMCPMC12569039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.